Landos Biopharma, Inc. (LABP): Price and Financial Metrics


Landos Biopharma, Inc. (LABP): $0.42

0.01 (+2.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LABP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LABP Stock Price Chart Interactive Chart >

Price chart for LABP

LABP Price/Volume Stats

Current price $0.42 52-week high $3.67
Prev. close $0.41 52-week low $0.21
Day low $0.41 Volume 106,175
Day high $0.45 Avg. volume 650,379
50-day MA $0.36 Dividend yield N/A
200-day MA $0.66 Market Cap 16.95M

Landos Biopharma, Inc. (LABP) Company Bio


Landos Biopharma, Inc. operates as a pharmaceutical company. The Company discovers and develops oral therapeutics for patients with autoimmune diseases. Landos Biopharma serves customers worldwide.


LABP Latest News Stream


Event/Time News Detail
Loading, please wait...

LABP Latest Social Stream


Loading social stream, please wait...

View Full LABP Social Stream

Latest LABP News From Around the Web

Below are the latest news stories about LANDOS BIOPHARMA INC that investors may wish to consider to help them evaluate LABP as an investment opportunity.

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that an abstract on its Phase 1b Study to evaluate safety, tolerability, pharmacokinetics and clinical efficacy of the Nucleotide-binding oligomerization do

Yahoo | January 11, 2023

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runw

Yahoo | January 5, 2023

Landos Biopharma Announces $16.7 Million Private Placement Financing

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private placement financing from the sale of pre-funded warrants to purchase an aggregate of 30,909,090 shares of its common stock at a price per pre-funded warrant of $0.54 to entities associated with Perceptive Advisors LLC, Landos’ largest

Yahoo | January 5, 2023

Landos Biopharma (LABP) Receives a Hold from JonesTrading

In a report released today, Sean Kim PhD from JonesTrading maintained a Hold rating on Landos Biopharma (LABP - Research Report). The company's shares closed today at $0.27.Kim PhD covers the Healthcare sector, focusing on stocks such as Concert Pharma, Satsuma Pharmaceuticals, and Ocuphire Pharma. According to TipRanks, Kim PhD has an average return of -10.9% and a 27.78% success rate on recommended stocks. Landos Biopharma has an analyst consensus of Hold, with a price target consensus of $3.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $15.00 and a one-year low of $0.22. Currently, Landos Biopharma has an average volume of 260.1K.

Austin Angelo on TipRanks | November 10, 2022

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming WeeksNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update. “Landos has made significant progress advancing our clinical-stage programs – omilancor, NX-13 an

Yahoo | November 10, 2022

Read More 'LABP' Stories Here

LABP Price Returns

1-mo -16.02%
3-mo 26.70%
6-mo -62.83%
1-year -87.76%
3-year N/A
5-year N/A
YTD -16.02%
2022 -89.58%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6565 seconds.